TKNO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.920

Open

2.920

VWAP

2.87

Vol

84.57K

Mkt Cap

155.94M

Low

2.770

Amount

242.43K

EV/EBITDA(TTM)

--

Total Shares

53.59M

EV

148.80M

EV/OCF(TTM)

--

P/S(TTM)

3.87

Alpha Teknova, Inc. is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It offers a range of standard and specialty pre-poured media plates for a variety of applications including bacteria, fungi, and nematode growth. Its two primary product categories include Lab Essentials and Clinical Solutions. Its core Lab Essentials products consist of commonly used catalog solutions and customer-specified formulations. Its Clinical Solutions products are custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.

Show More

Events Timeline

(ET)

2026-02-26

16:50:00

Teknova Reports Q4 Revenue of $9.98M, Exceeds Expectations

2026-02-26

16:50:00

Teknova Expects Total Revenue of $42M to $44M for FY 2026

2025-11-06 (ET)

2025-11-06

16:25:34

Alpha Teknova Supports FY25 Revenue Forecast of $39M-$42M, Aligning with Consensus of $40.61M

2025-11-06

16:24:31

Alpha Teknova Announces Q3 Earnings Per Share of 8 Cents, Below Consensus Estimate of 9 Cents

2025-08-14 (ET)

2025-08-14

08:30:08

new option listings on August 14th

2025-03-19 (ET)

2025-03-19

08:03:42

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

2025-03-11 (ET)

2025-03-11

19:02:32

Teknova, Pluristyx announce collaboration over next-generation cell therapies

2025-03-04 (ET)

2025-03-04

16:30:05

Alpha Teknova sees FY25 revenue f $39M -$42M, consensus $41.75M

2025-03-04

16:28:23

Alpha Teknova reports Q4 EPS (11c) vs. (26c) last year

News

NASDAQ.COM

02-27NASDAQ.COM

Alpha Teknova Reports Q4 Loss with Revenue Growth

seekingalpha

02-27seekingalpha

Alpha Teknova Q4 2025 Earnings Call Highlights

seekingalpha

02-26seekingalpha

Alpha Teknova Q4 Earnings Exceed Expectations

NASDAQ.COM

2025-11-07NASDAQ.COM

Alpha Teknova (TKNO) Third Quarter 2025 Earnings Call Transcript

NASDAQ.COM

2025-09-25NASDAQ.COM

IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation

TipRanks

2025-09-20TipRanks

Experts Forecast Potential 840% Surge for These 2 'Strong Buy' Penny Stocks

4 Analyst Rating

Wall Street analysts forecast TKNO stock price to rise

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

7.00

High

7.00

Current: 0.000

Low

7.00

Averages

7.00

High

7.00

Stephens

Stephens

maintain

$8

AI Analysis

2025-07-21

Reason

Stephens

Stephens

Price Target

$8

AI Analysis

2025-07-21

maintain

Reason

Stephens resumed coverage of Alpha Teknova with an Overweight rating and $8 price target. The company will benefit from growth in the biologics end market, the analyst tells investors in a research note. The firm believes Alpha continues to add to its clinical solutions customer base, which should drive revenue growth as demand ramps.

Valuation Metrics

The current forward P/E ratio for Alpha Teknova Inc (TKNO.O) is 0.00, compared to its 5-year average forward P/E of -11.84. For a more detailed relative valuation and DCF analysis to assess Alpha Teknova Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-11.84

Current PE

0.00

Overvalued PE

-0.78

Undervalued PE

-22.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-20.31

Current EV/EBITDA

-12.15

Overvalued EV/EBITDA

-3.35

Undervalued EV/EBITDA

-37.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

6.23

Current PS

3.23

Overvalued PS

10.69

Undervalued PS

1.77

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

yes adjust the filters to %70 and %7

Intellectia · 4 candidates

Region: USAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: AbovePrice, MoreAbovePriceMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Option Sentiments: BullishOne Week Rise Prob: >= 70One Week Predict Return: >= 7.0%Macd: bullish, positive

Ticker

Name

Market Cap$

Monte Rosa Therapeutics Inc

1.37B

Match Group Inc

7.31B

Southwest Gas Holdings Inc

6.46B

Alpha Teknova Inc

169.34M

Bullish penny stock tomorrow

Intellectia · 13 candidates

Market Cap: <= 750.00MRegion: USPrice: $0.50 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 70One Day Predict Return: >= 2.0%Macd: bullish

Ticker

Name

Market Cap$

Edesa Biotech Inc

11.35M

Carparts.Com Inc

46.18M

Cumberland Pharmaceuticals Inc

61.32M

BioNexus Gene Lab Corp

5.97M

Rani Therapeutics Holdings Inc

164.04M

Dyadic International Inc

30.38M

Whales Holding TKNO

Apollo Global Management, Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Alpha Teknova Inc (TKNO) stock price today?

The current price of TKNO is 2.91 USD — it has decreased -0.68

What is Alpha Teknova Inc (TKNO)'s business?

Alpha Teknova, Inc. is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It offers a range of standard and specialty pre-poured media plates for a variety of applications including bacteria, fungi, and nematode growth. Its two primary product categories include Lab Essentials and Clinical Solutions. Its core Lab Essentials products consist of commonly used catalog solutions and customer-specified formulations. Its Clinical Solutions products are custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.

What is the price predicton of TKNO Stock?

Wall Street analysts forecast TKNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TKNO is7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Alpha Teknova Inc (TKNO)'s revenue for the last quarter?

Alpha Teknova Inc revenue for the last quarter amounts to 9.98M USD, increased 7.76

What is Alpha Teknova Inc (TKNO)'s earnings per share (EPS) for the last quarter?

Alpha Teknova Inc. EPS for the last quarter amounts to -0.09 USD, decreased -18.18

How many employees does Alpha Teknova Inc (TKNO). have?

Alpha Teknova Inc (TKNO) has 158 emplpoyees as of April 21 2026.

What is Alpha Teknova Inc (TKNO) market cap?

Today TKNO has the market capitalization of 155.94M USD.